The recent addition of the Caris Assure liquid biopsy (Fig. 2) means the company can offer patients and biopharma partners access to a non-invasive liquid-profiling option. It also means that its ...
The firms will combine Caris' multimodal genomic data with Ontada's community oncology-based real-world data to support cancer drug development.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback